November 25, 2024 - 22:01

IceCure Medical Ltd. has announced that its next-generation multiprobe cryoablation technology has received a Notice of Allowance from Japan's Patent Office. This significant development marks a key milestone for the company's innovative approach to minimally invasive medical procedures.
The multiprobe cryoablation technology is designed to enhance the effectiveness and efficiency of cryoablation treatments, which are used to destroy abnormal tissues through extreme cold. This advancement is expected to provide physicians with improved tools for treating various medical conditions, potentially leading to better patient outcomes.
The approval from Japan's Patent Office underscores the technological advancements that IceCure is bringing to the field of cryoablation, positioning the company for growth in the competitive medical technology market.
July 4, 2026 - 00:42
BlackSky Technology (BKSY) Is Up 14.5% After Major NRO Contract Expansion And Equity-Paid BoardBlackSky Technology saw its stock price surge 14.5 percent in late June 2026 after the company announced a significant expansion of its contract with the National Reconnaissance Office. The updated...
July 3, 2026 - 02:30
Intel, Marvell Technology, and AMD Stocks Trade Down, What You Need To KnowA broad selloff hit semiconductor stocks in afternoon trading Thursday, with shares of Intel, Marvell Technology, and AMD all trading lower. The decline came as investors grew cautious over signs...
July 2, 2026 - 21:46
Who’s Regulating Police Technology? It’s Not the Courts.Public institutions are quietly handing over the authority to regulate policing technology to private industry, according to Texas A&M University School of Law professor Hannah Bloch-Wehba. In a...
July 2, 2026 - 04:52
Culture Pick | ‘Toy Story 5’ explores tension between toys, technologyThe latest chapter in the beloved animated franchise hit theaters on June 19, and it did not disappoint at the box office. `Toy Story 5,` directed by Pixar veteran Andrew Stanton, earned $312...